- Home
- ZEPP vs IRD Comparison
ZEPP vs IRD Comparison
Compare ZEPP & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- IRD
- Stock Information
- Founded
- ZEPP 2013
- IRD 2018
- Country
- ZEPP China
- IRD United States
- Employees
- ZEPP N/A
- IRD N/A
- Industry
- ZEPP Computer Manufacturing
- IRD
- Sector
- ZEPP Technology
- IRD
- Exchange
- ZEPP Nasdaq
- IRD NYSE
- Market Cap
- ZEPP 37.1M
- IRD 38.8M
- IPO Year
- ZEPP N/A
- IRD N/A
- Fundamental
- Price
- ZEPP $2.53
- IRD $0.95
- Analyst Decision
- ZEPP
- IRD Strong Buy
- Analyst Count
- ZEPP 0
- IRD 2
- Target Price
- ZEPP N/A
- IRD $7.00
- AVG Volume (30 Days)
- ZEPP 14.6K
- IRD 184.2K
- Earning Date
- ZEPP 05-19-2025
- IRD 05-15-2025
- Dividend Yield
- ZEPP N/A
- IRD N/A
- EPS Growth
- ZEPP N/A
- IRD N/A
- EPS
- ZEPP N/A
- IRD N/A
- Revenue
- ZEPP $182,603,000.00
- IRD $10,992,000.00
- Revenue This Year
- ZEPP $758.69
- IRD $22.00
- Revenue Next Year
- ZEPP N/A
- IRD $100.89
- P/E Ratio
- ZEPP N/A
- IRD N/A
- Revenue Growth
- ZEPP N/A
- IRD N/A
- 52 Week Low
- ZEPP $2.06
- IRD $0.65
- 52 Week High
- ZEPP $4.38
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- ZEPP 44.78
- IRD N/A
- Support Level
- ZEPP $2.51
- IRD N/A
- Resistance Level
- ZEPP $2.67
- IRD N/A
- Average True Range (ATR)
- ZEPP 0.17
- IRD 0.00
- MACD
- ZEPP 0.01
- IRD 0.00
- Stochastic Oscillator
- ZEPP 13.04
- IRD 0.00
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in two segments: Xiaomi Wearable Products and Self-branded products & others. The product portfolio includes smartwatches and fitness bands. The majority is from Self-branded products & other segments. It generates majority of the revenue from Xiaomi Wearable Products segment.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.